V1139
Anti-Vascular Endothelial Growth Factor Receptor 1 antibody produced in goat
affinity isolated antibody, lyophilized powder
Synonym(s):
Anti-Flt-1, Anti-VEGF R1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
MDL number:
UNSPSC Code:
51111800
biological source
goat
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
mouse
technique(s)
capture ELISA: 0.8 μg/mL
flow cytometry: 3-10 μg/mL
neutralization: suitable
western blot: 0.1-0.2 μg/mL
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
mouse ... Flt1(14254)
General description
Vascular endothelial growth factors receptors (VEGF Rs) are receptor tyrosine kinases that bind to VEGF that plays important role in embryonic vasculogenesis, angiogenesis and homeostasis. The biological effects of VEGF are mediated by VEGF R1 and VEGF R2 that have the ability to heterodimerize. The binding of VEGF to VEGF R1 results in activation of tyrosine amino acids of the cytoplasmic tail of the receptor. This interaction results in the activation of MAPK, PI3K, PKC, FAK and Src kinase pathways. The biological roles of VEGF R1 include in epithelial cell growth, proliferation, survival, migration and vascular permeability and angiogenesis.
Anti-Vascular Endothelial Growth Factor Receptor-1 recognizes mouse VEGF R1. Based on ELISA, the antibody shows <7% cross reactivity with recombinant human VEGF R1, 4% cross-reactivity with recombinant mouse VEGF164, 1% cross-reactivity with recombinant rat VEGF164, and 0.2% cross-reactivity with recombinant mouse VEGF R2 and VEGF R3.
Anti-Vascular Endothelial Growth Factor Receptor-1 recognizes mouse VEGF R1. Based on ELISA, the antibody shows <7% cross reactivity with recombinant human VEGF R1, 4% cross-reactivity with recombinant mouse VEGF164, 1% cross-reactivity with recombinant rat VEGF164, and 0.2% cross-reactivity with recombinant mouse VEGF R2 and VEGF R3.
Specificity
The antibody will neutralize the bioactivity of recombinant mouse VEGF R1 and can be used in the blockade of receptor-ligand interaction.
Immunogen
purified recombinant mouse VEGF R1 extracellular domain expressed in NSO cells.
Application
Anti-Vascular Endothelial Growth Factor Receptor 1 antibody may be used in immunoblotting at a working concentration of 0.1-0.2 μg/ml. For flow cytometry the recommended concentration is 3-10 μg/ml. For ELISA, a working concentration of 0.8 μg/ml may be used. The antibody is suitable for neutralization reactions.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline with 5% trehalsoe.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S Ananth Karumanchi et al.
Methods in molecular medicine, 122, 393-399 (2006-03-04)
Preeclampsia is characterized by the clinical triad of new hypertension, proteinuria, and edema after 20 wk of gestation. Recent evidence suggests that disturbances in angiogenic factors (such as vascular endothelial growth factor and placental growth factor) signaling and endothelial health
Hiroyuki Takahashi et al.
Clinical science (London, England : 1979), 109(3), 227-241 (2005-08-18)
The VEGF (vascular endothelial growth factor) family and its receptors are essential regulators of angiogenesis and vascular permeability. Currently, the VEGF family consists of VEGF-A, PlGF (placenta growth factor), VEGF-B, VEGF-C, VEGF-D, VEGF-E and snake venom VEGF. VEGF-A has at
Elizabeth Fleming et al.
BMC microbiology, 21(1), 278-278 (2021-10-16)
Genomics-driven discoveries of microbial species have provided extraordinary insights into the biodiversity of human microbiota. In addition, a significant portion of genetic variation between microbiota exists at the subspecies, or strain, level. High-resolution genomics to investigate species- and strain-level diversity
Masabumi Shibuya et al.
Experimental cell research, 312(5), 549-560 (2005-12-13)
The VEGF/VPF (vascular endothelial growth factor/vascular permeability factor) ligands and receptors are crucial regulators of vasculogenesis, angiogenesis, lymphangiogenesis and vascular permeability in vertebrates. VEGF-A, the prototype VEGF ligand, binds and activates two tyrosine kinase receptors: VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1).
Anna-Karin Olsson et al.
Nature reviews. Molecular cell biology, 7(5), 359-371 (2006-04-25)
Vascular endothelial growth-factor receptors (VEGFRs) regulate the cardiovascular system. VEGFR1 is required for the recruitment of haematopoietic precursors and migration of monocytes and macrophages, whereas VEGFR2 and VEGFR3 are essential for the functions of vascular endothelial and lymphendothelial cells, respectively.
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
